Form 4: Metsera Inc. Executive Brian Hubbard Granted Stock Options

Brian Hubbard, Chief Scientific Officer of Metsera, Inc., was granted stock options for 120,000 shares of common stock on May 20, 2025, according to a Form 4 filing.

Summary

• Brian Hubbard, the Chief Scientific Officer of Metsera, Inc., has been granted stock options.
• The options grant occurred on May 20, 2025.
• The options are for 120,000 shares of Metsera, Inc. common stock.
• The exercise price of the options is $29.25 per share.
• The options vest in 48 substantially equal monthly installments, beginning after the grant date.
• The options will be fully vested on the fourth anniversary of the grant date, contingent upon continued service.
• The expiration date for the options is May 19, 2035.
• Hubbard has granted power of attorney to Christopher Whitten, BernardChristopher Visioli, and Matthew Lang to handle SEC filings related to his Metsera holdings.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. It's a standard practice, so the sentiment is moderately positive as it indicates continued investment in key personnel.

Positives

• The granting of stock options to a key executive like the Chief Scientific Officer can be seen as an incentive to align their interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued service and contribution from the Chief Scientific Officer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key employees and align their interests with those of shareholders. This filing is a routine disclosure of such a grant.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• The vesting schedule of 48 months is a typical vesting period for stock options.
• Comparing the size of the grant (120,000 shares) to similar companies would require analyzing the company's overall equity compensation plan and the executive's role within the organization.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Scientific Officer to drive innovation and growth.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, Form 4, Metsera, Brian Hubbard, Chief Scientific Officer, insider transaction, equity compensation, power of attorney